Critical Review: Silo Pharma (NASDAQ:SILO) and Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences (NASDAQ:NBIX) and Silo Pharma (NASDAQ:SILO) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership.

Valuation and Earnings

This table compares Neurocrine Biosciences and Silo Pharma”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.86 billion	6.17	$478.60 million	$6.74	25.88
Silo Pharma	$70,000.00	41.84	-$4.23 million	($4.36)	-0.42

Neurocrine Biosciences has higher revenue and earnings than Silo Pharma. Silo Pharma is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Neurocrine Biosciences and Silo Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	18.98%	23.39%	16.22%
Silo Pharma	-6,726.39%	-81.75%	-66.35%

Institutional & Insider Ownership

92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 5.6% of Silo Pharma shares are held by institutional investors. 4.6% of Neurocrine Biosciences shares are held by company insiders. Comparatively, 3.6% of Silo Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Neurocrine Biosciences has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. Comparatively, Silo Pharma has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Neurocrine Biosciences and Silo Pharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0	4	19	1	2.88
Silo Pharma	1	0	0	0	1.00

Neurocrine Biosciences presently has a consensus target price of $202.32, suggesting a potential upside of 16.00%. Given Neurocrine Biosciences’ stronger consensus rating and higher probable upside, analysts clearly believe Neurocrine Biosciences is more favorable than Silo Pharma.

Summary

Neurocrine Biosciences beats Silo Pharma on 12 of the 14 factors compared between the two stocks.

About Neurocrine Biosciences

Neurocrine Biosciences is a biopharmaceutical company focused on developing and commercializing treatments for neurological, endocrine and related disorders. Founded in 1992 and headquartered in San Diego, California, the company conducts research and development alongside its commercial operations. Its marketed medicines include INGREZZA (valbenazine), approved in the United States for tardive dyskinesia and chorea associated with Huntington disease, and CRENESSITY (crinecerfont), used with glucocorticoid replacement therapy to treat classic congenital adrenal hyperplasia in adults and children.

About Silo Pharma

Silo Pharma, Inc. is a development-stage biopharmaceutical company focused on developing therapeutics that combine traditional pharmaceutical approaches with psychedelic research. The company’s programs are intended to address conditions involving pain, inflammation, neurological disorders, and mental health. Silo Pharma’s pipeline has included SP-26, an investigational ketamine-based implant designed to provide sustained drug delivery and being explored for conditions such as fibromyalgia. Its research portfolio has also included intranasal formulations and other therapeutics targeting disorders such as post-traumatic stress disorder and Alzheimer’s disease.